An interventional study of Questionnaire and Physical Exam in Gynecologic Cancers, Digestive Cancers and Urological Cancer, sponsored by Poitiers University Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In France, the number of new cancer cases across all cancer types was estimated at 382,000 in 2018. The impact of pain on a patient's quality of life is profound, with physical consequences (insomnia, fatigue, loss of appetite), psychological effects (anxiety, depression, demoralization, attention deficit, memory disorders), and social repercussions.
Acute pain induced by cancer, when poorly managed, can lead to the development of secondary chronic pain syndrome. The French National Authority for Health (Haute Autorité de Santé, HAS) deplores the late referral of patients with chronic pain, which complicates treatment and limits opportunities for improvement. Cancer-related pain has become a chronic condition in 50% of patients, leading to anxiety-depressive syndromes as well as social consequences such as social isolation or difficulty returning to professional activity.
In France, the 2017 White Paper by the SFETD (French Society for the Study and Treatment of Pain) notes that, despite three successive Cancer Plans integrating supportive care into the comprehensive management of cancer patients, one in three patients does not receive analgesic treatment appropriate to the intensity of their pain. To prevent chronic pain, the HAS recently recommended early assessment of acute pain (within less than a week) with a high-quality city-hospital organization.
This study proposes a systematic care pathway for the evaluation and treatment of pain in patients experiencing pain symptoms at the time of cancer diagnosis or relapse. A multidimensional pain assessment consultation will be conducted within 48 hours, along with the implementation of appropriate treatment. The patient will receive therapeutic education for self-assessment of pain, enabling the general practitioner to adjust analgesic treatments on an outpatient basis. The relevance of this pathway lies in the systematic assessment of pain and close collaboration between the general practitioner and the hospital, coordinated by a pain specialist. The general practitioner, who has an in-depth knowledge of the patient, should remain the primary coordinator of the patient's health pathway.
697 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.
This study's planned enrollment of 30 is below the median of 74 across 496 interventional studies indexed under Gastrointestinal Neoplasms.
Browse Gastrointestinal Neoplasms studies →Poitiers University Hospital is the lead sponsor of 315 studies on the registry; 63 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Non-Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Day 0: Multidimensional pain assessment (MPA) consultation conducted by a qualified paramedical professional (QPP) within 48 hours following the oncology consultation. Multidimensional pain will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF). The QPP transfers a report of this assessment to the general practitioner of the patient. Appropriate treatment of pain is implemented by the QPP. Day 2: Consultation with the general practitioner. Based on the report send by the QPP at day 0 and with the self-administration of the BPI-SF fulfilled by the patient at day 2, the general practitioner adjusts pain-relieving treatments if necessary. Day 7: MPA consultation conducted by the QPP who transfers a report of the BPI-SF assessment to the general practitioner. If the patient reports pain symptoms at day 7, then consultation with the general practitioner and MPA consultation are repeated ever week until resolution of pain symptoms.
Other: Questionnaire and Physical Exam
Brief Pain Inventory-Short Form is performed twice every week (for the multidimensional pain assessment consultation and for the general practitioner consultation) until resolution of the pain symptoms or up to day 28 (end of the study).
Proportion of eligible patients that provide a consent to participate
Patient's acceptability will be assessed if ≥ 80% of the eligible patients provide a signed consent.
Time frame: 1 day
Proportion of general pactitioner that confirmed their participation
General practitioner's acceptability will be assessed if ≥80% of the practitioners related to the eligible patients confirmed their participation.
Time frame: 2 days
Proportion of consultations with the general practitioner performed
Completion of consultations with the general practitioner will be assessed if ≥ 80% of the consultations with the general practitioner recommended by the pathway are completed.
Time frame: 28 days
Proportion of consultations at the hospital performed
Completion of consultations at the hospital will be assessed if ≥ 80% of the consultations at the hospital recommended by the pathway are completed.
Time frame: 28 days
Change in pain severity after 28 days
Pain severity is assessed using the dimension "pain severity" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain severity is defined as the difference of the two scores assessed at day 0 and at day 28. Pain severity score ranges from 0 (no pain) to 10 (severe pain).
Time frame: 28 days
Change in pain interference after 28 days
Pain interference is assessed using the dimension "pain interference" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain interference is defined as the difference of the two scores assessed at day 0 and at day 28. Pain interference score ranges from 0 (no pain) to 10 (severe pain).
Time frame: 28 days
Change in quality of life after 28 days
Quality of life is assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire). Change in quality of life is defined as the difference of the global quality of life scores assessed at day 0 and at day 28. Quality of life score ranges from 0 (worst quality of life) to 100 (best quality of life).
Time frame: 28 days
Proportion of patients requiring a specific pain management
Specific pain management includes: hospitalization due to the pain, referral to a pain management center, or referral to a mobile palliative care team.
Time frame: 28 days
Global satisfaction of the patients
Satisfaction of the patient will be assessed using a 5-point Likert scale (0 anchored with "not satisfied at all" and 4 anchored with "very satisfied")
Time frame: 28 days
Proportion of patients with a modified prescription by the general practitioner for analgesics treatments
The proportion of patients with a new analgesic treatment added or with a dose escalation or a dose reduction or a therapeutic switch
Time frame: 28 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.
Of 154 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 12 months is below that.
Counting every sponsor, half of 164 studies reached it within 36 months; a quarter within 17 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital →